These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 19835825)

  • 61. Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization.
    Gallichan WS; Rosenthal KL
    J Infect Dis; 1998 May; 177(5):1155-61. PubMed ID: 9592997
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine.
    Bernstein DI; Aoki FY; Tyring SK; Stanberry LR; St-Pierre C; Shafran SD; Leroux-Roels G; Van Herck K; Bollaerts A; Dubin G;
    Clin Infect Dis; 2005 May; 40(9):1271-81. PubMed ID: 15825029
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Herpes simplex virus 2 (HSV-2) infected cell proteins are among the most dominant antigens of a live-attenuated HSV-2 vaccine.
    Geltz JJ; Gershburg E; Halford WP
    PLoS One; 2015; 10(2):e0116091. PubMed ID: 25658852
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Herpes simplex virus type 2 vaccines: new ground for optimism?
    Aurelian L
    Clin Diagn Lab Immunol; 2004 May; 11(3):437-45. PubMed ID: 15138167
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Vaccination with a HSV-2 UL24 mutant induces a protective immune response in murine and guinea pig vaginal infection models.
    Visalli RJ; Natuk RJ; Kowalski J; Guo M; Blakeney S; Gangolli S; Cooper D
    Vaccine; 2014 Mar; 32(12):1398-406. PubMed ID: 24462481
    [TBL] [Abstract][Full Text] [Related]  

  • 66. B7 costimulation molecules expressed from the herpes simplex virus 2 genome rescue immune induction in B7-deficient mice.
    Thebeau LG; Vagvala SP; Wong YM; Morrison LA
    J Virol; 2007 Nov; 81(22):12200-9. PubMed ID: 17804511
    [TBL] [Abstract][Full Text] [Related]  

  • 67. In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model.
    Sin JI; Kim JJ; Boyer JD; Ciccarelli RB; Higgins TJ; Weiner DB
    J Virol; 1999 Jan; 73(1):501-9. PubMed ID: 9847356
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Replication-defective virus vaccine-induced protection of mice from genital herpes simplex virus 2 requires CD4 T cells.
    Morrison LA
    Virology; 2008 Jun; 376(1):205-10. PubMed ID: 18410949
    [TBL] [Abstract][Full Text] [Related]  

  • 69. DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2.
    Bourne N; Milligan GN; Schleiss MR; Bernstein DI; Stanberry LR
    Vaccine; 1996 Sep; 14(13):1230-4. PubMed ID: 8961510
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs.
    Bourne N; Bravo FJ; Francotte M; Bernstein DI; Myers MG; Slaoui M; Stanberry LR
    J Infect Dis; 2003 Feb; 187(4):542-9. PubMed ID: 12599070
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The Murine Intravaginal HSV-2 Challenge Model for Investigation of DNA Vaccines.
    Marshak JO; Dong L; Koelle DM
    Methods Mol Biol; 2020; 2060():429-454. PubMed ID: 31617196
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparison of intramuscular and footpad subcutaneous immunization with DNA vaccine encoding HSV-gD2 in mice.
    Jazayeri M; Soleimanjahi H; Fotouhi F; Pakravan N
    Comp Immunol Microbiol Infect Dis; 2009 Sep; 32(5):453-61. PubMed ID: 18571235
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Induction of innate immunity against herpes simplex virus type 2 infection via local delivery of Toll-like receptor ligands correlates with beta interferon production.
    Gill N; Deacon PM; Lichty B; Mossman KL; Ashkar AA
    J Virol; 2006 Oct; 80(20):9943-50. PubMed ID: 17005672
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Protection from genital herpes disease, seroconversion and latent infection in a non-lethal murine genital infection model by immunization with an HSV-2 replication-defective mutant virus.
    Diaz FM; Knipe DM
    Virology; 2016 Jan; 488():61-7. PubMed ID: 26609935
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Inactivated herpes simplex virus types 1 and 2 divaccine as an agent for effective immunoprophylaxis of recurrent genital herpes].
    Barinskiĭ IF; Makhmudov FR
    Vopr Virusol; 2010; 55(1):35-40. PubMed ID: 20364670
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial.
    ; Abu-Elyazeed RR; Heineman T; Dubin G; Fourneau M; Leroux-Roels I; Leroux-Roels G; Richardus JH; Ostergaard L; Diez-Domingo J; Poder A; Van Damme P; Romanowski B; Blatter M; Silfverdal SA; Berglund J; Josefsson A; Cunningham AL; Flodmark CE; Tragiannidis A; Dobson S; Olafsson J; Puig-Barbera J; Mendez M; Barton S; Bernstein D; Mares J; Ratner P
    Vaccine; 2013 Dec; 31(51):6136-43. PubMed ID: 23850416
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A recombinant multivalent combination vaccine protects against Chlamydia and genital herpes.
    Macmillan L; Ifere GO; He Q; Igietseme JU; Kellar KL; Okenu DM; Eko FO
    FEMS Immunol Med Microbiol; 2007 Feb; 49(1):46-55. PubMed ID: 17094789
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Immunodominant epitopes in herpes simplex virus type 2 glycoprotein D are recognized by CD4 lymphocytes from both HSV-1 and HSV-2 seropositive subjects.
    Kim M; Taylor J; Sidney J; Mikloska Z; Bodsworth N; Lagios K; Dunckley H; Byth-Wilson K; Denis M; Finlayson R; Khanna R; Sette A; Cunningham AL
    J Immunol; 2008 Nov; 181(9):6604-15. PubMed ID: 18941251
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effect of immunization with herpes simplex virus type-1 (HSV-1) glycoprotein D (gD) plus the immune enhancer GPI-0100 on infection with HSV-1 or HSV-2.
    Quenelle DC; Collins DJ; Marciani DJ; Kern ER
    Vaccine; 2006 Mar; 24(10):1515-22. PubMed ID: 16288820
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Optimized DNA Vaccine Enhanced by Adjuvant IL28B Induces Protective Immune Responses Against Herpes Simplex Virus Type 2 in Mice.
    Zhou Y; Wang Z; Xu Y; Zhang Z; Hua R; Liu W; Jiang C; Chen Y; Yang W; Kong W
    Viral Immunol; 2017 Oct; 30(8):601-614. PubMed ID: 28650722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.